

What is claimed is:

1. A pharmaceutical agent having the formula



wherein Peptide is a peptide having the formula  $aa_n$  where  $n$  is an integer  $\leq 40$ , Carrier is a member selected from the group consisting of cinnamoyl, benzoyl, phenylacetyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-dimethoxycinnamoyl, 3,4,5-trimethoxy-cinnamoyl, *t*-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylthoxycarbonyl, fumaroyl and derivatives thereof and Linker is a member selected from the group consisting of C6 to C16 lipidic chains and derivatives thereof, 8-amino-3,6-dioxaoctanoic acid and polymeric derivatives thereof, natural peptides, pseudopeptides of less than 4 residues, peptide mimics of less than 4 residues and combinations thereof.

2. The pharmaceutical agent of claim 1 wherein Linker is a member selected from the group consisting of natural peptides, pseudo peptides of less than 4 residues and peptide mimics of less than 4 residues.
3. The pharmaceutical agent of claim 1, wherein  $n$  is an integer of from 3 to 6.
4. The pharmaceutical agent of claim 1, wherein  $n$  is 5.
5. The pharmaceutical agent of claim 1, wherein Peptide is Tyr-Gly-Gly-Phe-Met.
6. The pharmaceutical agent of claim 1 wherein Carrier is a member selected from the group consisting of cinnamoyl,

3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3-methoxycinnamoyl, 3,4-dimethoxycinnamoyl, and 3,4,5-trimethoxy-cinnamoyl.

7. The pharmaceutical agent of claim 1 wherein Carrier is cinnamoyl.

8. The pharmaceutical agent of claim 1 wherein Linker is a -C6 or C8 acidic moiety.

9. The pharmaceutical agent of claim 1 wherein Linker is  $G \psi (CH_2-CH_2) G$ .

10. The pharmaceutical agent of claim 1 wherein Peptide is an epitope or an immune sequence characteristic of an infectious, viral or cancerous disease.

11. A pharmaceutical composition for administration to a patient in need thereof comprising a pharmaceutical agent according to claim 1 and one or more pharmaceutically acceptable adjuvants.

12. The pharmaceutical composition of claim 11 wherein the composition is formulated for oral administration.

13. The pharmaceutical composition of claim 11 wherein the composition is formulated for parenteral administration.

14. The pharmaceutical composition of claim 11 wherein the composition is formulated for intravenous administration.

15. The pharmaceutical composition of claim 11 wherein the composition releases a biologically active form of the pharmaceutical agent into the patient's system at physiologically effective levels over a period of time of up to twelve hours.

16. The pharmaceutical composition of claim 11 wherein the composition releases a biologically active form of the pharmaceutical agent into the patient's system at physiologically effective levels over a period of time of up to twenty-four hours.
17. The pharmaceutical composition according to claim 11 wherein Peptide is an epitope or an immune sequence characteristic of an infectious, viral or cancerous disease.
18. A method for treatment of a physiological condition through administration of a peptide species comprising the steps of chemically linking a peptide of the general formula  $aa_n$ , where aa is an amino acid, and where n is an integer  $\leq 40$ , to an alkyl or aryl carrier moiety to form a pro-drug, and administering the pro-drug to a patient exhibiting the physiological condition.
19. The method of claim 18 wherein the peptide is poorly absorbed orally.
20. A method for the treatment of a physiological condition which comprises administering a pharmaceutical agent according to claim 1 to a patient exhibiting the physiological condition.
21. The method according to claim 20 wherein the pharmaceutical agent is administered orally or parenterally.
22. A method for the treatment of a physiological condition which comprises administering a pharmaceutical agent having the formula Carrier — Linker<sub>x</sub> — Peptide wherein X is 0 or 1, Peptide is a peptide having the formula  $aa_n$ , wherein n is an integer  $\leq 40$ , Carrier is a member selected from the group consisting of cinnamoyl, benzoyl, phenylacetyl, 3-OH-cinnamoyl, 3,4-methylene-dioxycinnamoyl, 3-

methoxycinnamoyl, 3,4-dimethoxycinnamoyl, 3,4,5-trimethoxycinnamoyl, *t*-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a member selected from the group consisting of C6 to C16 lipidic chains and derivatives thereof, 8-amino-3,6-dioxaoctanoic acid and polymeric derivatives thereof, natural peptides, pseudopeptides of less than 4 residues, peptide mimics of less than 4 residues and combinations thereof.

23. The method for the treatment of a physiological condition according to claim 22 which comprises administering a pharmaceutical agent wherein x is 0 and Carrier — Peptide is a pro-drug.

24. The method for the treatment of a physiological condition according to claim 22 which comprises administering a pharmaceutical composition wherein x is 1 and Carrier — Linker — Peptide is a pro-drug.